Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7.
Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–57.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22(2):417–26.
Bhowmik D, Hines DM, Intorcia M, Wade RL. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. J Med Econ. 2018;21(6):622–8.
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–66.
Silbermann R, Roodman GD. Myeloma bone disease: pathophysiology and management. J Bone Oncol. 2013;2(2):59–69.
Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12(8):743–52.
Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, Legiec W, Krejci M, Laribi K, Zhu L, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–81.
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council adult Leukaemia working party. J Clin Oncol. 2005;23(36):9219–26.
Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010;24(5):1043–9.
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–7.
Wisloff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol. 2005;75(4):293–8.
Bhowmik D, Shi N, Manjelievskaia J, Song X, Vidito S, Intorcia M. Impact of skeletal-related events on multiple myeloma treatment [abstract]. J Clin Oncol. 2018;36(15 suppl). https://doi.org/10.1200/JCO.2018.1236.1215_suppl.e20009.
Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data. J Bone Oncol. 2019;14:100215.
Nash Smyth E, Conti I, Wooldridge JE, Bowman L, Li L, Nelson DR, Ball DE. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. J Med Econ. 2016;19(5):477–86.
Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ. 2016;17(6):711–21.
Ashcroft J, Duran I, Hoefeler H, Lorusso V, Lueftner D, Campioni M, Intorcia M, Bahl A. Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: results from a prospective, multinational, observational study. Eur J Haematol. 2018;100(5):479–87.
Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52.
Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281(4):365–82.
Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism. 2018;80:80–90.
Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.
European Medicines Agency: Zometa (zoledronic acid). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf. Accessed 18 Dec 2018.
Electronic medicines compendium: Disodium pamidronate. Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/32673. Accessed 17 Dec 2018.
Electronic medicines compendium: Bonefos (disodium clodronate tetrahydrate). Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/309. Accessed 17 Dec 2018.
European Medicines Agency: XGEVA (denosumab). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed 17 Dec 2018.
Yee AJ, Raje NS. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncol. 2018;14(3):195–203.
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–37.
Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(8):812–8.
National Comprehensive Cancer Network: Clinical practice guidelines in oncology. Multiple myeloma Version 2.2019. https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed 17 Dec 2018.
Lebret T, Casas A, Cavo M, Woll PJ, Deleplace C, Kennedy C, Schoen P, Jackisch C. The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey. Eur J Cancer Care (Engl). 2017;26(4):e12490.
Kim C, Hernandez RK, Cyprien L, Liede A, Cheng PC. Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data. Support Care Cancer. 2018;26(8):2833–41.
Qian Y, Bhowmik D, Kachru N, Hernandez RK, Cheng P, Liede A. Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data. Support Care Cancer. 2018;26(3):807–12.
Ashcroft J, Bagguley T, Smith A, Wang H-I, Howell D, Sayala HA, Cook G, Jack A, Patmore R, Roman E. Skeletal-related events in myeloma: a population-based study [abstract]. Blood. 2013;122(21):3158.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28(33):4976–84.
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–57.
Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.
World Health Organization: Analgesic ladder. http://www.who.int/cancer/palliative/painladder/en/. Accessed 17 Dec 2018.
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–64.
Hoefeler H, Duran I, Hechmati G, Garzon Rodriguez C, Luftner D, Ashcroft J, Bahl A, Atchison C, Wei R, Thomas E, et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective–prospective observational study – a cohort from 4 European countries. J Bone Oncol. 2014;3(2):40–8.
Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, Wright JD, Hershman DL, Lentzsch S, et al. Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma. J Natl Compr Cancer Netw. 2019;17(1):22–8.
Bhowmik D, Song X, Intorcia M, Gray S, Shi N. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population. Curr Med Res Opin. 2019;35(3):513–23.
Intorcia M, Hohmann D, Giannopoulou C, Ansorge S, Diel I: Occurrence of skeletal-related events (SREs) in patients with solid tumours and bone metastasis (ST/BM): early versus late initiation of SRE preventative agents (SPA) [abstract PS051]. Presented at the MASCC/ISOO Annual Meeting, 28–30 June 2018, Vienna, Austria.
Qian Y, Bhowmik D, Bond C, Wang S, Colman S, Hernandez RK, Cheng P, Intorcia M. Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States. Cancer Med. 2017;6(7):1523–30.
McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA, O'Donnell E. Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. Cancer Med. 2019;8(1):374–82.
Hinge M, Andersen KT, Lund T, Jorgensen HB, Holdgaard PC, Ormstrup TE, Ostergaard LL, Plesner T. Baseline bone involvement in multiple myeloma – a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients. Haematologica. 2016;101(10):e415–8.
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52–61.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23(9):1545–56.
Mateos M, Cavo M, Fink L, Koneswaran N, Giannopoulou C, Niepel D, Gonzalez-McQuire S, Intorcia M. Patient characteristics, skeletal-related events (SRE) and renal impairment (RI) in patients with multiple myeloma (MM): a patient chart audit in EU5. Value Health. 2017;20(9):A413 abstract PCN411.